Concord Biotech Ltd

Concord Biotech Ltd’s shares touched a fresh 52-week low of Rs.1121 today, marking a significant decline amid a broader market recovery. The stock has underperformed its sector and benchmark indices, reflecting ongoing pressures on its financial performance and valuation metrics.

Concord Biotech Ltd’s stock price declined to a fresh 52-week low of Rs.1157 today, marking a significant milestone in its ongoing downward trajectory. The pharmaceutical and biotechnology company’s shares have been under pressure, reflecting a combination of subdued financial performance and broader market dynamics.

Concord Biotech Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 23 October 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 31 January 2026, providing investors with the latest insights into its performance and outlook.

Concord Biotech Ltd’s shares declined to a fresh 52-week low of Rs.1159 on 30 Jan 2026, marking a significant drop amid sustained underperformance relative to its sector and benchmark indices. The stock’s latest intraday low represents a near 53% fall from its 52-week high of Rs.2451.65, reflecting ongoing pressures on the company’s financial metrics and market sentiment.

Concord Biotech Ltd’s stock declined sharply to a fresh 52-week low of Rs.1175.65 today, marking a significant downturn as the pharmaceutical and biotechnology company continues to face headwinds. The stock has underperformed its sector and broader market indices, reflecting ongoing pressures on its financial performance and valuation metrics.

Concord Biotech Ltd’s stock declined sharply to a fresh 52-week low of Rs.1175.65 on 28 Jan 2026, marking a significant downturn amid a sustained period of underperformance relative to its sector and broader market indices.

Concord Biotech Ltd’s shares declined to a fresh 52-week low of Rs.1211.1 on 27 Jan 2026, marking a significant milestone in the stock’s ongoing downward trajectory. The pharmaceutical and biotechnology company’s stock has underperformed both its sector and the broader market, reflecting a series of financial and valuation pressures.

Concord Biotech Ltd’s stock touched a fresh 52-week low of Rs.1225.3 today, marking a significant decline amid a sustained downward trajectory over the past year. This new low reflects ongoing pressures on the company’s financial performance and valuation metrics within the Pharmaceuticals & Biotechnology sector.

Concord Biotech Ltd’s stock declined to a fresh 52-week low of Rs.1278.05 today, marking a significant milestone in its ongoing downward trajectory. The stock has underperformed its sector and broader market indices, reflecting persistent pressures on its financial performance and valuation metrics.

Concord Biotech Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 23 October 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 20 January 2026, providing investors with the latest insights into the company’s performance and outlook.

Concord Biotech Ltd’s share price declined to a fresh 52-week low of Rs.1292.35 today, marking a significant downturn amid a broader market that showed resilience. The stock’s performance over the past year has been notably weaker than the benchmark Sensex, reflecting a combination of subdued financial results and valuation concerns.

Concord Biotech Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 23 October 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 09 January 2026, providing investors with the latest insights into its performance and outlook.

Concord Biotech Ltd’s stock touched a new 52-week low of Rs.1296.75 today, marking a significant decline amid a sustained period of underperformance relative to the broader market and its sector peers. This fresh low reflects ongoing pressures on the company’s financial metrics and valuation, despite a modest rebound following two consecutive days of decline.

Concord Biotech Ltd’s stock price declined to a fresh 52-week low of Rs.1313.05 today, marking a significant milestone in its ongoing downward trajectory. The pharmaceutical and biotechnology company’s shares have underperformed both their sector and the broader market, reflecting a series of financial setbacks and valuation concerns.

Concord Biotech Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 23 October 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 29 December 2025, providing investors with the latest insights into its performance and outlook.

Concord Biotech's shares reached a fresh 52-week low of Rs.1318.8 today, marking a significant decline amid a broader market rally. The stock has underperformed its sector and major indices, reflecting ongoing pressures on its financial performance and valuation metrics.

Concord Biotech’s share price reached a new 52-week low of Rs.1318.85 today, marking a significant decline amid subdued market conditions and company-specific performance trends. The stock has been trading below all key moving averages, reflecting ongoing pressures within the Pharmaceuticals & Biotechnology sector.

Concord Biotech’s shares reached a fresh 52-week low of Rs.1318.85 today, marking a significant decline amid broader market fluctuations. The stock has been trading below all key moving averages and has recorded losses over the past two sessions, reflecting ongoing pressures within the Pharmaceuticals & Biotechnology sector.